Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s Antiplatelet Agent Brilinta Superior To Plavix In Phase III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

But Lilly/Daiichi’s pending Effient has done the same thing, albeit with increased bleeding. Full PLATO data, to be released in August, will be scrutinized for safety.
Advertisement

Related Content

AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?
AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?
Can The Medicines Company Rebound From A Phase III Blow?
Can The Medicines Company Rebound From A Phase III Blow?
The Return Of The Blockbuster? Stage Is Set For Prasugrel Approval
AstraZeneca’s Oral Anticoagulant AZD0837 Phase III Program Pushed Back To 2009
AstraZeneca’s Oral Anticoagulant AZD0837 Phase III Program Pushed Back To 2009
Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix

Topics

Advertisement
UsernamePublicRestriction

Register

PS069406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel